• Test Code:
  • Department:
  • Test Synonyms:
    B-ALLT-ALLAMLAML+MDSCLLDLBCLFAGliomaHES/CMML/MPDMDSMMMZLNSCLC1p36/1q2519p13/19q134/10/17 ALL5p15/15q22 MM3 centromere8 centromere12 centromereABL1 break-apartABL2 break-apartAFF1 break-apartALK break-apartATM BCL2 break-apartBCL3 break-apartBCL6 break-apartBCR/ABL+/- ASS t(9;22)BIRC3(API2)/MALT1 t(11;18) BRAF CBFB/MYH11 inv(16) CCND1 break-apartCDKN2A (p16)CHIC2/FIPIL1/PDGFRACHOP (DDIT3) break-apartCKS1B/CDKN2C MMC-METC-MYCCOL1A1/PDGFB (DFSP) t(17;22)CRLF2 break-apartD13S319/13q34 D20S108 D7S486 DEK/NUP214 t(6;9) E2A break-apartE2A/PBX1 t(1;19) EGFR EGR1 ETV6 (TEL) break-apartETV6/RUNX1 (TEL/AML) t(12;21)EVI1 break-apartEWSR1 break-apartFGFR1 FGFR1 break-apartFOXO1 (FKHR) break-apartFUS break-apartHER-2/neu (ERBB2)IGH break-apartIGH/BCL2 t(14;18)IGH/CCND1 t(11;14)IGH/CCND3 t(6;14)IGH/FGFR3 t(4;14)IGH/MAF t(14;16)IGH/MAFB t(14;20)IGH/MALT1 t(14;18)IGH/MYC t(8;14)IGK break-apartIGL break-apartIL3 break-apartJAK2 break-apartMALT1 break-apartMDM2MECOM/GATAMLL (KMT2A) break-apartMLL/MLLT1 t(11;19)MLLT3/MLL t(9;11)MYB/6q21MYC break-apartN-MYC NUP98 break-apartPDGFRB break-apartPML/RARA t(15;17)PTEN RARA break-apartRB1/D13S319/LAMP1RET break-apartROS1 break-apartRUNX1 break-apartRUNX1T1/RUNX1 (ETO/AML) t(8;21)SS18 (SYT) break-apartTCL1 break-apartTP53 (p53)TRAD (TCR) break-apart X&Y post-transplant
  • CPT Code(s):

Knight Diagnostic Laboratories have an extensive menu of probes for hematologic and solid tumor analyses by fluorescent-in situ-hybridization (FISH) techniques.  Karyotypic analysis and FISH testing are key components in the diagnosis of hematologic malignancies. Recently, FISH has become an essential component in therapeutic decisions for solid tumor patients as well.  Tests are developed quickly after clinical utility has been established.


Slides are prepared per standard protocols and 100-200 interphase cells are scored for each probe under fluorescence microscopy.  FISH can also be performed on sections of formalin-fixed, paraffin-embedded tumor tissue; slides are prepared per standard protocols and 100 interphase cells are scored.  For tumor samples on FFPE, testing includes a pathologist review of each tumor slide prior to FISH testing.  For multiple myeloma, blood or bone marrow cells are sorted on CD138+ prior to FISH.

Specimen Requirements:

Bone Marrow: 
Shortly before aspiration add 0.2 cc of Sodium Heparin (1,000 units/ml) to tube of transport medium (please contact lab to arrange for transport medium to be sent).  Add at least 1 cc of bone marrow aspirate to the tube and suspend well.  Allow no clots to form.

Peripheral blood:
May be used if bone marrow is inaspirable and blasts (.5%) are present.  Send in Sodium Heparin tube.

Bone core biopsy:
May also provide cells in cases where marrow is severely packed.  Send in transport medium with Sodium Heparin.

Bone marrow smears:
Provide 10 slides

Formalin-fixed paraffin-embedded tumor block or FFPE slides:  

  • If sending slides, please include H&E stained slide cut from same block
  • Preferred slice thickness is 4-5 microns on positively charged slides.
  • The number of slides needed will change based on the number of probes used. Please submit 3-5 slides for a single probe test, with an additional 1-2 slides for each additional probe to be tested.
  • Store at room temperature.
  • Contact Client Services at (855) 535-1522 for shipping supplies and instructions

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information, including ethnicity, clinical history, and family history.

Test Performed (Days):

Mon - Sat

Turn Around Time:

3-7 days* *TAT may be extended if part of a chromosome study

Shipment Sensitivity Requirements:

  • Ship via overnight express, using the FedEx priority overnight label provided.
  • Contact Client Services at (855) 535-1522 for shipping kits and instructions.


Additional Info:

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More